A carregar...
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
Na minha lista:
| Publicado no: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4545857/ https://ncbi.nlm.nih.gov/pubmed/26208852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0192-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|